New York, NY / August 6, 2014 / Matinas BioPharma (OTCBB:MTNB) published a new blog post today on The Chairman’s Blog, written by the Company’s President and Chief Executive Officer, Mr. Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
In his inaugural blog, he discussed his insight into the Lipidomics field and how Matinas is unique from other omega-3 companies. Mr. Rongen also expands on the Company’s lead product candidate, MAT9001, for the treatment of severe hypertriglyceridemia. Read the full blog post from Mr. Rongen on TheChairmansBlog.com (http://www.thechairmansblog.com/matinas-biopharma/roelof-rongen/lipidomics-exciting-foundation-matinas-biopharma/).
About Matinas BioPharma
Matinas BioPharma is a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic diseases. Led by an experienced and highly successful management team and a board of directors with a history of building highly successful pharmaceutical companies, Matinas is focused on creating the next generation of omega-3-fatty-acid-based pharmaceutical products. Our lead product, MAT9001, which takes advantage of advancements in the field of lipidomics, has been specifically designed and formulated for therapeutic applications in the dyslipidemia field. For more information, please visit www.matinasbiopharma.com.
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com
SOURCE: The Chairmans Blog